secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2025-11-26T23:59:59+00:00
Accession:  0001437749-25-036452
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals replaces auditor Salberg & Company with Weinberg & Company
------------------------------------------------------------------------------

- Engaged Weinberg & Company as independent auditor for FY ending Dec 31, 2025, effective Nov 20, 2025.
- Dismissed Salberg & Company on Nov 24, 2025; no disagreements or reportable events in prior years.
- Salberg's prior audit opinions contained a going-concern explanatory paragraph but were otherwise unqualified.
- Weinberg had previously audited Dura Medical LLC, a subsidiary acquired by Hope Therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/0001437749-25-036452-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774925036452/nrxp20251125_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-036452

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer